Remimazolam showed a non-inferior incidence of (POD) and (EA) compared to dexmedetomidine, with rates of 20.73% and 10.98%, respectively.
The incidence of POD was 20.73% in the remimazolam group and 18.75% in the dexmedetomidine group.
The incidence of EA was 10.98% in the remimazolam group compared to 8.75% in the dexmedetomidine group.
No significant differences were found in the Quality of Recovery-15 (QoR-15) or numeric rating scale (NRS) scores for pain between the two groups.
Patients receiving remimazolam exhibited more stable hemodynamics, requiring fewer opioids and vasopressors during surgery.
Group D had lower Athens Insomnia Scale (AIS) scores on postoperative day 1.
A significant correlation was observed between hypotension, EA, and POD.
Simplified
BACKGROUND AND AIM: (POD) and (EA) are common complications in older patients undergoing video-assisted thoracoscopic surgery (VATS), significantly impacting recovery. This study was designed to examine whether remimazolam is noninferior to dexmedetomidine for preventing POD and EA in elderly patients following VATS.
PATIENTS AND METHODS: A total of 176 elderly patients scheduled for VATS due to lung cancer were randomly assigned to receive either dexmedetomidine (Group D, n = 88) or remimazolam (Group R, n = 88). Group D received dexmedetomidine at 0.5 μg/kg/h starting 3 minutes before anesthesia induction until surgery completion. Group R received remimazolam at 0.5 mg/kg/h over the same period. The primary outcomes were the incidence of EA and POD within 5 days after surgery. Secondary outcomes included Quality of Recovery-15 (QoR-15) score, Athens Insomnia Scale (AIS), and numeric rating scale (NRS) for pain. Correlations among hypotension, EA, and POD were also analyzed.
RESULTS: The incidence of POD and EA in Group R was non-inferior to that in Group D (non-inferiority < 0.01), with overall rates of 20.73% vs 18.75% and 10.98% vs 8.75%, respectively. No significant differences were observed in QoR-15 or NRS scores between groups, though Group D had lower AIS scores on postoperative day 1. Group R demonstrated more stable intraoperative hemodynamics with reduced requirements for opioids and vasopressors, and shorter extubation times. Hypotension and EA were significantly correlated with POD. P
CONCLUSION: Remimazolam was non-inferior to dexmedetomidine in preventing POD and EA in elderly patients undergoing VATS while providing improved hemodynamic stability and reducing the need for intraoperative opioids and vasopressors.
Key numbers
20.73%
Incidence
Incidence in remimazolam group vs. dexmedetomidine group.
10.98%
Incidence
Incidence in remimazolam group vs. dexmedetomidine group.
30 μg
Opioid Usage Reduction
Sufentanil dosage in remimazolam group vs. dexmedetomidine group.
Full Text
We can’t show the full text here under this license.
